Print

CytoDyn Announces Entry into Agreement With Progenics Pharmaceuticals, Inc. (PGNX) to Acquire PRO 140  
7/31/2012 9:51:52 AM

LUTZ, Fla.--(BUSINESS WIRE)--CytoDyn Inc. (the "Company") (OTCQB:CYDY), a development stage biotechnology company focused on the development of new therapies for combating infection with immune deficiency virus and other antibody applications, announced today that the Company and Progenics Pharmaceuticals, Inc. ("Progenics") have entered into an asset purchase agreement, effective as of July 25, 2012 (the "Agreement"), pursuant to which the Company intends to acquire from Progenics its proprietary humanized monoclonal antibody HIV viral-entry inhibitor drug candidate, PRO 140 ("PRO 140").
//-->